Fatigue in patients with rheumatic diseases

Joint Bone Spine

Volumn 78, Issue 2, 2011, Pages 156-160

  Dupond, Jean Louis ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Asthenia; Depression; Fatigue; Rheumatic disease

Indexed keywords

CITALOPRAM; ETANERCEPT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ASTHENIA; DEPRESSION; ENERGY EXPENDITURE; FATIGUE; HUMAN; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; QUALITY OF LIFE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SLEEP DISORDER; STRESS;

DEPRESSION; ENERGY METABOLISM; FATIGUE; HUMANS; PREVALENCE; RHEUMATIC DISEASES; SEROTONIN UPTAKE INHIBITORS;

EID: 79952251586     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.05.002     Document Type: Short Survey

References (75)

1. Repping-Wuts H., Van Riel P., Van Achterberg T. Rheumatologists' knowledge, attitude and current management of fatigue in patients with rheumatoid arthritis (RA). Clin Rheumatol 2008, 27:1549-1555.
2. Hewlett S., Cockshott Z., Byron M., et al. Patient's perception of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005, 53:697-702.
3. Hider S.L., Tanveer W., Brownfield A., et al. Depression in RA patients treated with anti-TNF is common and under recognized in the rheumatology clinic. Rheumatology 2009, 48:1152-1154.
4. TenchCM, Mc Curdie I., White P.D., et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 2000, 39:1249-1254.
5. Repping-Wuts H., Fransen J., Van Achterberg T., et al. Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs 2007, 16:377-383.
6. Barendregt P.J., Visser M.R., Smets E.M., et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998, 57:291-295.
7. Thombs B.D., Taillefer S.S., Hudson M., et al. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007, 57:1089-1093.
8. Moses A., Fisher M., Yazia Y. Behcet's syndrome patients have high levels of functional disability, fatigue and pain as measured by Multi-Dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol 2008, 4(Suppl. S):110-113.
9. Turan Y., Duruöz M.T., Bal S., et al. Assessment of fatigue in patients with ankylosing spondylitis. Rheumatol Int 2007, 2:847-857.
10. Manuel de psychiatrie 1960, Masson, Paris. H. Ey, P. Bernard, C.H. Brisset (Eds.).
11. Pavic M., Cathebras P., Debourdeau P. Asthénie: orientation diagnostique. Diagnostics difficiles en médecine interne 2008, 111-119. Maloine, Paris. H. Rousset, D. Vital Durand, J.L. Dupond, M. Pavic (Eds.).
12. Delalande S., de Seze J., Fauchais A.L., et al. Neurologic manifestations in primary Sjögren's syndrome. A study of 82 patients. Medicine 2004, 83:280-291.
13. Agarwall V., Singh R., Wiclaf C.H., et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol 2005, 27:841-844.
14. Harboe E., Tjensvall A.B., Maroni S., et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren's syndrome: a comparative population -based study. Ann Rheum Dis 2009, 68:1541-1546.
15. Honczarenko K., Budzianowska A., Ostanek L. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol 2008, 42:513-517.
16. Greenberg B.M. The neurologic manifestations of systemic lupus erythematosus. Neurologist 2009, 15:115-121.
17. Bekkelund S.I., Torbergsen T., Husby G., et al. Myopathy and neuropathy in rheumatoid arthritis. A quantitative controlled electromyographic study. J Rheumatol 1999, 26:2348-2351.
18. Terrier B., Lanoix C., Guillevin L., et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum 2007, 57:1520-1529.
19. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Clinical and pathological perspectives. Am J Med 1987, 82:447-455.
20. Kiltz U.T.A., Fendler C., Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy. Three examples. J Rheumatol 2008, 35:2074-2076.
21. Lindvall B., Bengtsson A., Ernerudh J., et al. Subclinical myositis is common in primary Sjögren's syndrome and is not related to muscle pain. J Rheumatol 2008, 29:717-725.
22. Yood R.A., Smith T.W. Inclusion body myositis and systemic lupus erythematosus. J Rheumatol 1985, 12:568-570.
23. Musial J., Undes A., Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003, 42:1566-1568.
24. Vermino S., Hopkins S., Wang Z. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 2009, 146:3-7.
25. Dupond J.L., Gil H., Bouladdi M., et al. Acute dysautonomia secondary to autoimmune diseases: efficacy of intravenous immunoglobulin and correlation to plasma norepinephrine levels. Clin Exp Rheumatol 1999, 17:733-736.
26. Dupond J.L., Gil H., de Wazieres B. Five years efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren's syndrome. Am J Med 1999, 106:125.
27. Yukawa S., Tahara K., Shoji A., et al. Acute pandysautonomia as well as central nervous system involvement and peripheral neuropathy in a patient with systemic lupus erythematosus. Med Rhumatol 2008, 15:516-521.
28. Bergman M.J., Shahouri S.S., Shaver T.S., et al. Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis and fibromyalgia. J Rheumatol 2009, 36:2788-2794.
29. Davis M.C., Zantra A.J., Younger J., et al. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 2009, 23:1104-1108.
30. Harboe E., Tjensvoll A.B., Vefring H.K., et al. Fatigue in primary Sjögren's syndrome - a link to sickness behaviour in animals?. Brain Behav Immun 2009, 23:110-118.
31. Moreland L.W., Genovese M.C., Sato R., et al. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006, 55:287-293.
32. Omdal R., Mellgren S.I., Koldingsnes W., et al. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies or other disease characteristics. J Rheumatol 2002, 29:48-56.
33. Hartkam A., Geenen R., Bijl M., et al. Serum cytokine levels related to multiple dimension of fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis 2004, 63:133-137.
34. Burgos P.I., Alarçon G.S., McGwin G., et al. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum 2009, 61:1179-1186.
35. Ramos-Casals M., Cervera R., Yagüe J., et al. Cryoglobulinemia in primary Sjögren's syndrome - prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998, 28:200-205.
36. Garcia-Carresco M., Ramos-Casals M., Cervera R., et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001, 30:366-373.
37. El-Sherif W.T., El Gendi S.S., Ashmawy M.M., et al. Thyroid disorders and auto antibodies in systemic lupus erythematosus and rheumatoid arthritis patients. Egypt J Immunol 2004, 11:81-90.
38. D'Arbonneau F., Ansart S., Le Berre R., et al. Thyroid dysfunction in primary Sjögren's syndrome: a long-term follow-up study. Arthritis Rheum 2003, 49:804-809.
39. Bowness P., Shetliff K., Middleniss A., et al. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. Rheumatology 1991, 30:349-351.
40. Kramer C.K., Tourinho T.F., Castro W.P., et al. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Arch Med Res 2005, 36:54-58.
41. Pacilio M., Migliaresi S., Mali R., et al. Elevated bioactive prolactin levels in systemic lupus erythematosus - association with disease activity. J Rhumatol 2001, 28:16-21.
42. Leanos-Miranda A., Pascoe-Lira D., Chavez-Rueda K.A., et al. Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001, 28:1546-1553.
43. Walker S.E., Mc Murray R.W., Houri J.M., et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann N Y Acad Sci 1998, 840:762-772.
44. Walker S.E., Smarr K.L., Parker J.C., et al. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine. Lupus 2000, 9:527-533.
45. Zietz B., Reber T., Oertel M., et al. Altered function of the hypothalamic stress axis in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol 2000, 27:911-918.
46. Cutolo M., Villagio B., Otsa K., et al. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun Rev 2005, 4:497-502.
47. Johnson E.O., Vlachoyiannopoulos P.G., Skopouli F.N., et al. Hypofunction of the stress axis in Sjögren's syndrome. J Rheumatol 1998, 25:1508-1514.
48. Hartkamp A., Geenen R., Godaert G.L., et al. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus. A randomised controlled trial. Am Rheum Dis 2010, 69:1144-1147.
49. Attout H., Guez S., Durand J., et al. Hypoparathyroidism in systemic lupus erythematosus. Joint Bone Spine 2007, 74:282-284.
50. Gazzaruso C., Montecucco C.M., Geroldi D., et al. Severe hypercalcemia and systemic lupus erythematosus. Joint Bone Spine 2000, 67:485-488.
51. Pertovaara M., Korpela M., Kouri T., et al. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. Rheumatology 1999, 38:1113-1120.
52. Taylor-Gjevre R.M., Gjevre J.A., Skomo R., et al. Restless legs syndrome in a rheumatoid arthritis patient cohort. J Clin Rheumatol 2009, 15:12-15.
53. Gudbjörnsson B., Broman J.E., Hetta J., et al. Sleep disturbance in patients with primary Sjögren's syndrome. Br J Rheumatol 1993, 32(1072):6.
54. Staud R. Are patients with systemic lupus erythematosus at increased risk for fibromyalgia. Curr Rheumatol Rep 2006, 8:430-435.
55. Dhir V., Lawrence A., Aggarwal A., et al. Fibromyalgia is common and adversely affects pain and fatigue perception in North Indian patients with rheumatoid arthritis. J Rheumatol 2009, 36:2443-2448.
56. Ostuni P., Botsios C., Sfriso P., et al. Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis and Sjögren's syndrome. Minerva Med 2002, 93:203-209.
57. Wolfe F., Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 2009, 61:667-673.
58. Isik A., Koca S.S., Ozturk A., et al. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 2007, 26:872-878.
59. Stojanovich L., Zandman-Goddard G., Pavlovich S., et al. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007, 6:421-426.
60. Brey R.L., Holliday S.L., Saklad A.R., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1216-1220.
61. Valtysdottir S.T., Gudbjörnsson B., Lindqvist, et al. Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol 2000, 27:165-169.
62. Huyser B.A., Parker J.C., Thoreson R., et al. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998, 41:2230-2237.
63. Segal B., Thomas W., Rogers T., et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum 2008, 59:1780-1787.
64. Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Ann N Y Acad Sci 2001, 933:222-234.
65. O'Brien J.M., Scott L.V., Dinan J.C. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004, 19:397-403.
66. Hinz A, Krauss O, Hauss J.P., et al. Anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care 2009. doi:1111/j.1365-2354.2009.O1088.
67. Kozora E., Ellison M.C., West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006, 55:628-635.
68. Euller-Ziegler L., Bonhomme P., Gagnerie F., et al. Rheumatoid polyarthritis and life events. Rev Rhum Mal Osteoartic 1985, 52:563-569.
69. Kozora E., Ellison M.C., Waxmonsky J.A., et al. Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005, 14:363-372.
70. Karaiskos D., Mavragani L.P., Makaroni S., et al. Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis 2009, 68:40-46.
71. Dupond J.L., Humbert P., Taillard C., et al. Relationship between autoimmune diseases and personality traits in women. Presse Med 1990, 19:2019-2022.
72. Bai M., Tomensen B., Creed F., et al. The role of psychological distress and personality variables in the disablement process in rheumatoid arthritis. Scand J Rheumatol 2009, 38:419-430.
73. Ishii H., Nagashima M., Tanno M., et al. Does being easily moved tears as a response to psychological stress reflect response to treatment and the general prognosis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:611-616.
74. Dagfinrud H., Vollestad N.K., Loge J.H., et al. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005, 53:5-11.
75. Sacre S., Medghalchi M., Gregory B., et al. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 2010, 62:683-693.